| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
CPH Stock Overview
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada.
Cipher Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$2.43 |
| 52 Week High | CA$2.80 |
| 52 Week Low | CA$1.54 |
| Beta | 1.39 |
| 1 Month Change | 10.96% |
| 3 Month Change | 1.67% |
| 1 Year Change | 23.35% |
| 3 Year Change | 94.40% |
| 5 Year Change | -50.41% |
| Change since IPO | -34.32% |
Recent News & Updates
Here's Why I Think Cipher Pharmaceuticals (TSE:CPH) Is An Interesting Stock
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Shareholder Returns
| CPH | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | 9.0% | 2.6% | 1.5% |
| 1Y | 23.4% | -62.8% | 2.1% |
Return vs Industry: CPH exceeded the Canadian Pharmaceuticals industry which returned -61.8% over the past year.
Return vs Market: CPH exceeded the Canadian Market which returned 2.1% over the past year.
Price Volatility
| CPH volatility | |
|---|---|
| CPH Average Weekly Movement | 3.8% |
| Pharmaceuticals Industry Average Movement | 12.3% |
| Market Average Movement | 10.6% |
| 10% most volatile stocks in CA Market | 18.9% |
| 10% least volatile stocks in CA Market | 4.2% |
Stable Share Price: CPH is less volatile than 75% of Canadian stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: CPH's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 5 | Craig Mull | https://www.cipherpharma.com |
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. Its commercial products include Epuris (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; Ozenoxacin to treat adult and paediatric patients with impetigo; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream that reduces the growth of unwanted facial hair in women; BRINAVESS, a treatment for sinus rhythm in adults; and AGGRASTAT, an intravenous anti-platelet drug. The company’s licensed products comprise CIP-Isotretinoin; Lipofen (CIP-Fenofibrate), a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; and Conzip/Durela (CIP- Tramadol), a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain.
Cipher Pharmaceuticals Inc. Fundamentals Summary
| CPH fundamental statistics | |
|---|---|
| Market Cap | CA$60.98m |
| Earnings (TTM) | CA$10.21m |
| Revenue (TTM) | CA$27.58m |
6.0x
P/E Ratio2.2x
P/S RatioIs CPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CPH income statement (TTM) | |
|---|---|
| Revenue | US$21.34m |
| Cost of Revenue | US$3.92m |
| Gross Profit | US$17.42m |
| Other Expenses | US$9.52m |
| Earnings | US$7.90m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.31 |
| Gross Margin | 81.64% |
| Net Profit Margin | 37.04% |
| Debt/Equity Ratio | 0% |
How did CPH perform over the long term?
See historical performance and comparison